Allena Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview

Allena Pharmaceuticals

30/07/2021 15:04

* Allena Pharmaceuticals Inc  ALNA.OQ   ALNA.O  is expected
to show a no change in quarterly revenue when it reports
results on August 3 (estimated). 
​* Refinitiv's mean analyst estimate for Allena Pharmaceuticals
Inc is for a loss of 21 cents per share. For the same quarter
last year, the company reported a loss of 26 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Allena
Pharmaceuticals Inc is $6.5​, about 85.3% above​ its last
closing price of $0.96. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.22       -0.23      -0.21     Beat    7.7
 Dec. 31 2020  -0.19       -0.19      -0.24     Missed  -24.4
 Sep. 30 2020  -0.21       -0.21      -0.22     Missed  -3.4​
 Jun. 30 2020  -0.27       -0.30      -0.26     Beat    13.2
 Mar.          -0.43​      -0.45      -0.31     Beat    31.1​
 31​ 2020​                                              
 Dec. 31 2019  -0.54       -0.53      -0.47     Beat    11.6​
 Sep. 30 2019  -0.46       -0.49      -0.57     Missed  -15.9
 Jun. 30 2019  -0.53       -0.54      -0.54     Met     -0.6
 This summary was machine generated July 30 at 14:04 GMT.  All
figures in US dollars unless otherwise stated